CARDIAC TROPONIN-C AS A TARGET PROTEIN FOR A NOVEL CALCIUM SENSITIZING DRUG, LEVOSIMENDAN

The role of cardiac troponin C (cTnC) as a target protein for the calc ium sensitization by levosimendan, pimobendan, MCI-154 and EMD 53998 w as evaluated using purified recombinant human cTnC. For determination of calcium- and magnesium-dependent binding of the compounds to cTnC a new type of cTnC-HPLAC column was used. Furthermore, dansylated cTnC was utilized to study the effect of the calcium sensitizing compounds on calcium-induced conformation of cTnC. Only levosimendan showed calc ium-dependent and to a lesser extent magnesium-dependent retention in the cTnC column. The findings indicate that levosimendan binds both to the N-terminal and C-terminal domains of cTnC. In agreement with this , only levosimendan shifted the calcium-induced fluorescence curve of dansylated cTnC to the left. In the control experiments Ca-50 and K-Ca (2+) were calculated to be 2.73 mu M and 4 x 10(5)M(-1), respectively. Levosimendan at 3 mu M decreased the value of Ca-50 to 1.19 mu M. In conclusion, it is suggested that the mechanism of calcium sensitizing effect of levosimendan, unlike that of the other calcium sensitizers, is based on calcium-dependent binding to the N-terminal domain of cTnC . This is proposed to amplify the trigger of contraction induced by cT nC in the cardiac muscle. (C) 1995 Academic Press Limited (C) 1995 Aca demic Press Limited